Cargando…
Local Treatment of Breast Cancer Liver Metastasis
Breast cancer represents a leading cause of death worldwide. Despite the advances in systemic therapies, the prognosis for patients with breast cancer liver metastasis (BCLM) remains poor. Especially in case of failure or cessation of systemic treatments, surgical resection for BCLMs has been consid...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770644/ https://www.ncbi.nlm.nih.gov/pubmed/31514362 http://dx.doi.org/10.3390/cancers11091341 |
_version_ | 1783455524046503936 |
---|---|
author | Bale, Reto Putzer, Daniel Schullian, Peter |
author_facet | Bale, Reto Putzer, Daniel Schullian, Peter |
author_sort | Bale, Reto |
collection | PubMed |
description | Breast cancer represents a leading cause of death worldwide. Despite the advances in systemic therapies, the prognosis for patients with breast cancer liver metastasis (BCLM) remains poor. Especially in case of failure or cessation of systemic treatments, surgical resection for BCLMs has been considered as the treatment standard despite a lack of robust evidence of benefit. However, due to the extent and location of disease and physical condition, the number of patients with BCLM who are eligible for surgery is limited. Palliative locoregional treatments of liver metastases (LM) include transarterial embolization (TAE), transarterial chemoembolization (TACE), and selective internal radiotherapy (SIRT). Percutaneous thermal ablation methods, such as radiofrequency ablation (RFA) and microwave ablation (MWA), are considered potentially curative local treatment options. They are less invasive, less expensive and have fewer contraindications and complication rates than surgery. Because conventional ultrasound- and computed tomography-guided single-probe thermal ablation is limited by tumor size, multi-probe stereotactic radiofrequency ablation (SRFA) with intraoperative image fusion for immediate, reliable judgment has been developed in order to treat large and multiple tumors within one session. This review focuses on the different minimally invasive local and locoregional treatment options for BCLM and attempts to describe their current and future role in the multidisciplinary treatment setting. |
format | Online Article Text |
id | pubmed-6770644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67706442019-10-30 Local Treatment of Breast Cancer Liver Metastasis Bale, Reto Putzer, Daniel Schullian, Peter Cancers (Basel) Review Breast cancer represents a leading cause of death worldwide. Despite the advances in systemic therapies, the prognosis for patients with breast cancer liver metastasis (BCLM) remains poor. Especially in case of failure or cessation of systemic treatments, surgical resection for BCLMs has been considered as the treatment standard despite a lack of robust evidence of benefit. However, due to the extent and location of disease and physical condition, the number of patients with BCLM who are eligible for surgery is limited. Palliative locoregional treatments of liver metastases (LM) include transarterial embolization (TAE), transarterial chemoembolization (TACE), and selective internal radiotherapy (SIRT). Percutaneous thermal ablation methods, such as radiofrequency ablation (RFA) and microwave ablation (MWA), are considered potentially curative local treatment options. They are less invasive, less expensive and have fewer contraindications and complication rates than surgery. Because conventional ultrasound- and computed tomography-guided single-probe thermal ablation is limited by tumor size, multi-probe stereotactic radiofrequency ablation (SRFA) with intraoperative image fusion for immediate, reliable judgment has been developed in order to treat large and multiple tumors within one session. This review focuses on the different minimally invasive local and locoregional treatment options for BCLM and attempts to describe their current and future role in the multidisciplinary treatment setting. MDPI 2019-09-11 /pmc/articles/PMC6770644/ /pubmed/31514362 http://dx.doi.org/10.3390/cancers11091341 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bale, Reto Putzer, Daniel Schullian, Peter Local Treatment of Breast Cancer Liver Metastasis |
title | Local Treatment of Breast Cancer Liver Metastasis |
title_full | Local Treatment of Breast Cancer Liver Metastasis |
title_fullStr | Local Treatment of Breast Cancer Liver Metastasis |
title_full_unstemmed | Local Treatment of Breast Cancer Liver Metastasis |
title_short | Local Treatment of Breast Cancer Liver Metastasis |
title_sort | local treatment of breast cancer liver metastasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770644/ https://www.ncbi.nlm.nih.gov/pubmed/31514362 http://dx.doi.org/10.3390/cancers11091341 |
work_keys_str_mv | AT balereto localtreatmentofbreastcancerlivermetastasis AT putzerdaniel localtreatmentofbreastcancerlivermetastasis AT schullianpeter localtreatmentofbreastcancerlivermetastasis |